MarketMoodz
UBS guidance: Pharmaceuticals as a safe-haven hedge in ongoing market turmoil
UBS argues that pharmaceutical stocks offer a defensive hedge as market turmoil intensifies and traditional havens falter. A CNBC summary of a UBS research note led by Andrew Garthwaite says investors should hide in pharma, though the note has not yet been independently disclosed by UBS.
Key Takeaways
- Pharma stocks offer defensive ballast with a close inverse correlation to PMI and risk proxies.
- Eli Lilly and Merck are rated Buy by UBS, with Lilly up about 34% and Merck about 35% over the last six months.
- Pharma is among the least leveraged sectors and could benefit from AI-driven productivity gains in R&D.
- The sector is the seventh-most shorted globally (out of 29), signaling potential upside if short-covering occurs.
- Oil prices surpass $100 per barrel while spot gold slides over 2% in five days, signaling a shift in safe-haven dynamics.
People Involved
- Andrew Garthwaite UBS Strategist
Entities Involved
- UBS Group AG Swiss investment bank and asset manager
- Eli Lilly and Co. (LLY) Pharmaceutical company
- Merck & Co. (MRK) Pharmaceutical company
MarketMoodz Analysis
If UBS’s framework holds, investors may tilt toward selected defensive names in pharma as market stress rises. Pharma’s balance sheets are relatively low-leverage, valuations are defendable, and Andrew Garthwaite’s note points to a close inverse with PMI and other risk proxies, suggesting pharma could dampen portfolio drawdowns even as risk appetite wobbles. This implies a hedging tilt rather than broad sector rotation into cyclicals.
Historically, crises have accelerated liquidity-driven rotations toward defensives; pharma has often provided ballast when equity risk premia widen and commodity shocks push energy costs higher. The combination of modest leverage, potential AI-driven productivity gains in R&D, and relatively cheap valuations could support multiple expansion in select pharma names even as traditional havens falter. Investors should monitor PMI data, short-interest dynamics, and UBS’s primary release to confirm the thesis as the situation evolves.
What to watch next: confirm UBS’s primary document and the exact correlation figures to PMI and risk proxies; monitor oil and gold price trajectories, PMI readings around 52, and any changes in pharma short-interest, AI productivity metrics, and earnings signals from Lilly and Merck.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial